Physician profile
Jasjit K Singh
NPI 1265466197
$419,741.11
in general payments reported to CMS, 2019-2025
29 companies · $169K in 2025
The $169K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $12K · 2021: $19K · 2022: $45K · 2023: $55K · 2024: $67K · 2025: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $171K · Honoraria: $45K · Consulting Fee: $38K · Travel and Lodging: $25K · Food and Beverage: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,875 · Education: $34.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $170,747.00 |
| Honoraria | $45,225.00 |
| Consulting Fee | $38,036.00 |
| Travel and Lodging | $25,329.26 |
| Food and Beverage | $10,031.22 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,875.00 |
| Education | $34.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $178,064.43 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105,343.98 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $72,456.70 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $40,850.44 | 2024-2025 | Cobenfy |
| Allergan, INC. | $8,584.34 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $5,564.07 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $3,627.50 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $740.26 | 2019-2025 | Rexulti, Brintellix |
| Otsuka America Pharmaceutical, INC. | $650.08 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $604.40 | 2019-2025 | Ingrezza |
| Corium, LLC | $587.44 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $544.73 | 2019-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $508.92 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $422.18 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $269.89 | 2019-2025 | Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $145.34 | 2024-2025 | Qelbree |
| Shire North American Group INC | $139.15 | 2019 | |
| Collegium Pharmaceutical, INC. | $134.94 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2021 | |
| Tris Pharma INC | $81.37 | 2019-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $76.13 | 2019-2024 | Jornay Pm |
| Sage Therapeutics, LLC | $72.03 | 2022-2025 | Zurzuvae |
| Eisai INC. | $34.31 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $30.68 | 2023-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $19.75 | 2019 | |
| Indivior INC. | $18.45 | 2024 | Perseris |
| Alfasigma USA, INC. | $16.10 | 2021 | |
| Neos Therapeutics, Lp | $14.82 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.